Treatment of pancreatic cancer with intravenous vitamin C: a case report.
Treatment of pancreatic cancer with intravenous vitamin C: a case report.
复制标题
DOI：
10.1097/cad.0000000000000603
复制
发表时间：
2018-04
影响因子：
2.3
通讯作者：
Levine M
中科院分区：
文献类型：
--
作者：
Drisko JA;Serrano OK;Spruce LR;Chen Q;Levine M
胰腺导管腺癌(PDA)预后很差，通常在晚期被发现，治疗方案很少。目前PDA的常规治疗方案与显著的发病率、降低的生活质量和相当大的经济负担相关。因此，在诊断出PDA后，一些患者转向中西医结合治疗作为替代选择。静脉注射药理抗坏血酸(PAA)就是这样一种治疗方法。多年来，PAA的使用一直备受争议，但最近更严格的科学研究表明，与口服相比，静脉注射抗坏血酸时，血液浓度有显著差异。这种药理上的差异似乎对它在肿瘤学中的作用至关重要。在这里，我们报告了在低分化的IV期PDA患者中使用PAA作为一种唯一的化疗方案。患者在确诊后存活了近4年，PAA是他唯一的治疗方法，他的疾病实现了客观的消退。他死于败血症和器官衰竭，死于肠穿孔事件。此病例说明了PAA有效控制肿瘤进展的可能性，并作为标准的PDA化疗方案的辅助治疗。在设计未来的治疗试验时，应该考虑我们患者的PAA经验，以及以前在细胞、动物和临床实验中的研究。
Pancreatic ductal adenocarcinoma (PDA) has a dismal prognosis and is often discovered at an advanced stage with few therapeutic options. Current conventional regimens for PDA are associated with significant morbidity, decreased quality of life, and a considerable financial burden. As a result, some patients turn to integrative medicine therapies as an alternate option after a diagnosis of PDA. Intravenous pharmacologic ascorbic acid (PAA) is one such treatment. The use of PAA has been passionately debated for many years, but more recent rigorous scientific research has shown that there are significant blood concentration differences when ascorbic acid is given parenterally when compared to oral dosing. This pharmacologic difference appears to be critical for its role in oncology. Here, we report the use of PAA in a patient with poorly differentiated stage IV PDA as an exclusive chemotherapeutic regimen. The patient survived nearly 4 years after diagnosis, with PAA as his sole treatment, and he achieved objective regression of his disease. He died from sepsis and organ failure from a bowel perforation event. This case illustrates the possibility of PAA to effectively control tumor progression and serve as an adjunct to standard of care PDA chemotherapy regimens. Our patient’s experience with PAA should be taken into consideration, along with previous research in cell, animal, and clinical experiments to design future treatment trials.